US$ 20.27
dual gip and glp-1 receptor agonist Potential Use of GIP/GLP-1 Agonists for Respiratory Disorders: Where Are We at? The Sustained Effects of a
Description
We need to do our own research

21 November 2014

Exenatide, dapagliflozin, or Phentermine/Topiramate differentially affect metabolic profiles in polycystic ovary syndrome

Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists

The risk of hypoglycemia with GLP-1 RAs is low when used as monotherapy

Chang, S
